Abstract
The immunogenicity of therapeutic factor VIII (FVIII) in patients with haemophilia A remains a critical issue in patient management. This review describes the immunological processes involved in the activation of the immune system against FVIII, with a particular focus on the role of endocytic receptors for the recognition of FVIII by antigen-presenting cells.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies / blood*
-
Antigen-Presenting Cells / immunology*
-
Antigen-Presenting Cells / metabolism
-
Blood Coagulation*
-
CD4-Positive T-Lymphocytes / immunology
-
Coagulants / administration & dosage
-
Coagulants / immunology*
-
Coagulants / metabolism
-
Endocytosis*
-
Factor VIII / administration & dosage
-
Factor VIII / immunology*
-
Factor VIII / metabolism
-
Hemophilia A / blood
-
Hemophilia A / drug therapy*
-
Hemophilia A / immunology
-
Humans
-
Receptors, Cell Surface / metabolism*
Substances
-
Antibodies
-
Coagulants
-
Receptors, Cell Surface
-
Factor VIII